DMD trial returns more positive data for synthetic steroid

Swiss specialty pharma company Santhera Pharmaceuticals (SIX: SANN) and privately-held US firm ReveraGen BioPharma have announced positive top-line results for their Duchenne muscular dystrophy (DMD) candidate vamorolone.

Vamorolone, a synthetic steroid, represents a new class of treatment for people with DMD, binding to the same receptors as corticosteroids but offering a potentially favorable safety profile.

After 48 weeks, data from the VISION-DMD study show maintenance of efficacy across all parameters, following the 24-week dataset required for registration purposes.